Abstract:Key PointsTopoisomerase I (TOP1) enzymes are essential in higher eukaryotes, as they are required to relax DNA supercoiling generated by transcription, replication and chromatin remodelling.Topoisomerases are particularly vulnerable to topoisomerase I inhibitors during their cleavage reaction, which is referred to as the 'cleavage complex'.TOP1 can be trapped by anticancer drugs as it cleaves DNA. Moreover, TOP1 can be trapped by endogenous alterations to DNA (mismatches, abasic sites, nicks and adducts) and apoptotic alterations to chromatin.Camptothecin is a natural product of which TOP1 is the only cellular target. Two camptothecin derivatives have recently been approved by the US Food and Drug Administration: topotecan for ovarian and lung cancers and irinotecan for colorectal cancer.Various non-camptothecin inhibitors of TOP1 are in development, including indolocarbazole, phenanthridine and indenoisoquinoline derivatives. Non-camptothecins are expected to be active in cancers that are currently resistant to camptothecins, and to have a greater therapeutic index.Co-crystal structures of TOP1 inhibitors illustrate the interfacial inhibition paradigm by which a small drug molecule can trap conformational intermediates of macromolecular complexes (in the case of TOP1 inhibitors, the TOP1 enzyme and its cleaved DNA substrate).The cytotoxic activity of TOP1 inhibitors is related to the interference of trapped TOP1 cleavage complexes with DNA replication and transcription.Deficiencies in both the checkpoint and DNA-repair pathways determine cellular sensitivity to TOP1 inhibitors. Therefore, the identification of such deficiencies in tumours should guide the rational use of TOP1 inhibitors. Targeting checkpoint and repair pathways should also increase the selectivity of TOP1 inhibitors in tumours that have pre-existing deficiencies in relevant redundant pathways.

Screening of Antitumor Compounds from Natural Compounds or Its Derivatives by Using the Recombinant Human DNA Topoisomerase Ⅰ As Target

Systematic analysis of natural topoisomerase I inhibitors from Forsythiae Fructus by ultrafiltration-UPLC-ESI-MS/MS, pharmacophore modelling, and molecular dynamics simulation

Affinity Ultrafiltration of DNA Topoisomerases-Targeted Compounds Determined with HPLC/ESI-MS for Drug Candidate Screening

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

Genetic Engineering Strategies for Purification of Recombinant Proteins from Canola by Anion Exchange Chromatography: An Example of β‐Glucuronidase

Unravelling the role of natural and synthetic products as DNA topoisomerase inhibitors in hepatocellular carcinoma

Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors

Design, Synthesis and Structure-Activity Relationship Studies of Glycosylated Derivatives of Marine Natural Product Lamellarin D

PROSPECTS FOR SEARCHING MULTITARGET TOPOISOMERASE INHIBITORS WITH ANTITUMOR PROPERTIES

New Approach for Screening Anti-Tumor Compounds

Screening and Identification of Small Molecule Compounds Perturbing Mitosis Using Time-Dependent Cellular Response Profiles.

Synthesis and Biological Evaluation of Xanthone Derivatives As Anti-Cancer Agents Targeting Topoisomerase II and DNA

Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I

Synthesis, insecticidal activity and inhibition on topoisomerase I of 20(S)-t-Boc-amino acid derivatives of camptothecin

Targeting Topoisomerase I in the Era of Precision Medicine

Synthesis and Biological Evaluation of N -(Carbobenzyloxy)- L -Phenylalanine and N -(Carbobenzyloxy)- L -Aspartic Acid- Β -Benzyl Ester Derivatives As Potent Topoisomerase IIα Inhibitors

A Yeast-Based Screening System for Differential Identification of Poisons and Suppressors of Human Topoisomerase I

Effects of yeast culture addition (Saccharomyces cerevisiae) to Anatolian water buffalo diets on milk composition and somatic cell count.

Topoisomerase I inhibitors: camptothecins and beyond

Design, Synthesis and Antitumor Activity of Non-Camptothecin Topoisomerase I Inhibitors

Antitumor and Topoisomerase Ⅱα Inhibitory Activities of 3-Aryl-7-hydroxyquinolines